PROLIXIN DECANOATE Drug Patent Profile

When do Prolixin Decanoate patents expire, and what generic alternatives are available?

Prolixin Decanoate is a drug marketed by Bristol Myers Squibb and is included in one NDA.

The generic ingredient in PROLIXIN DECANOATE is fluphenazine decanoate. There is one drug master file entry for this compound. Nine suppliers are listed for this compound. Additional details are available on the fluphenazine decanoate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Prolixin Decanoate

A generic version of PROLIXIN DECANOATE was approved as fluphenazine decanoate by FRESENIUS KABI USA on July 14^th, 1987.

Summary for PROLIXIN DECANOATE

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	60
Patent Applications:	2,482
DailyMed Link:	PROLIXIN DECANOATE at DailyMed

US Patents and Regulatory Information for PROLIXIN DECANOATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bristol Myers Squibb	PROLIXIN DECANOATE	fluphenazine decanoate	INJECTABLE;INJECTION	016727-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Prolixin Decanoate Market Dynamics and Financial Trajectory

Last updated: August 5, 2026

Prolixin Decanoate, the long-acting injectable formulation of fluphenazine decanoate, is a mature generic antipsychotic with limited commercial visibility, low pricing power, and no meaningful branded-growth profile. Its market is sustained by clinical demand for depot treatment in schizophrenia, institutional use, and a small number of generic suppliers. Financial performance is driven by supply continuity, manufacturing economics, and periodic shortages rather than innovation, patent exclusivity, or market expansion.

What is Prolixin Decanoate and how is it used?

Prolixin Decanoate is an intramuscular depot formulation of fluphenazine, a first-generation phenothiazine antipsychotic. It is used for maintenance treatment of patients with schizophrenia who require a long-acting formulation or have adherence difficulties with oral therapy.[1]

Product attribute	Description
Active ingredient	Fluphenazine decanoate
Drug class	First-generation antipsychotic
Dosage form	Intramuscular depot injection
Common strengths	25 mg/mL and 50 mg/mL presentations have historically been marketed
Primary indication	Schizophrenia
Administration	Deep intramuscular injection
FDA pathway	Original NDA product followed by generic injectable approvals
Market status	Mature, largely genericized product
Biosimilar exposure	None

The depot formulation releases fluphenazine over an extended period. FDA labeling describes an effective duration that can extend for several weeks, although dosing intervals vary by patient response and clinical judgment.[1]

The product is clinically differentiated from oral fluphenazine because it reduces daily dosing requirements. Its disadvantages include extrapyramidal symptoms, tardive dyskinesia, hyperprolactinemia, neuroleptic malignant syndrome, and injection-related administration requirements. Second-generation long-acting injectables, including paliperidone palmitate, aripiprazole monohydrate, and aripiprazole lauroxil, compete for the same adherence and relapse-prevention segment but have more recent clinical development and stronger commercial support.[2]

When did Prolixin Decanoate lose exclusivity?

Prolixin Decanoate has no economically relevant remaining originator exclusivity. The active pharmaceutical ingredient and depot formulation are based on an old phenothiazine molecule, and the product has been marketed for decades.

The original Prolixin brand was associated with Bristol-Myers Squibb and related commercial entities. Later distribution and generic supply arrangements changed over time. The commercial value of the original brand declined as generic fluphenazine decanoate became available.

Exclusivity category	Current commercial relevance
New chemical entity exclusivity	Expired decades ago
Original formulation patents	Expired or no longer commercially material
Pediatric exclusivity	Not a relevant current barrier
Orphan-drug exclusivity	None
Regulatory exclusivity	None known to provide meaningful market protection
Patent-term extension	Not relevant to current sales
Generic competition	Established

Because the core molecule and depot technology are old, a new entrant does not face the conventional patent cliff associated with recently approved branded drugs. The principal barriers are manufacturing validation, sterile injectable production, regulatory approval, distribution, and reliable access to active pharmaceutical ingredient.

What patents protect Prolixin Decanoate?

No active patent estate is known to provide meaningful exclusivity for the historical Prolixin Decanoate product. The product’s commercial protection is primarily regulatory and manufacturing-based rather than patent-based.

The relevant intellectual-property position can be summarized as follows:

IP category	Assessment
Fluphenazine compound patents	Historical patents are expired
Decanoate ester technology	Historical protection is expired or commercially immaterial
Depot formulation patents	No major current blocking estate is publicly associated with Prolixin Decanoate
Method-of-use patents	No current patent position appears to constrain generic maintenance treatment
Device patents	Limited relevance because the product is administered by syringe and vial
Manufacturing patents	Potentially relevant at the supplier level, but unlikely to create broad market exclusivity
Orange Book patents	No commercially significant active listing is expected for this mature product

A detailed Orange Book determination should distinguish between the discontinued branded product, current generic products, and any active FDA application. FDA’s Orange Book identifies approved products and patent certifications, but older generic injectable products may have limited patent data when no active patents remain.[3]

What is the FDA regulatory status of Prolixin Decanoate?

The FDA-approved product category is fluphenazine decanoate injection. Product labeling establishes the dosage form, route, contraindications, warnings, and dosing information.[1]

The FDA regulatory profile is mature:

1. The original branded product was approved before the modern generic market structure was established.
2. Generic fluphenazine decanoate injections entered through abbreviated new drug applications.
3. Generic applicants generally demonstrate pharmaceutical equivalence and bioequivalence or rely on FDA’s applicable requirements for injectable products.
4. The market does not require biosimilar development because fluphenazine decanoate is a chemically synthesized small molecule, not a biologic.
5. Regulatory risk centers on sterile manufacturing, product quality, supply continuity, and post-market safety.

The principal warnings reflect the safety profile of first-generation antipsychotics. FDA labeling includes warnings relating to tardive dyskinesia, neuroleptic malignant syndrome, mortality in elderly patients with dementia-related psychosis, and other serious adverse reactions.[1]

How many companies market fluphenazine decanoate?

The number of active suppliers can change because generic manufacturers may discontinue products, transfer applications, or maintain approval without continuous commercial distribution. The market has historically included generic injectable manufacturers such as Hikma Pharmaceuticals and other U.S. generic suppliers.

The relevant competitive structure is narrow:

Competitor type	Competitive effect
Generic fluphenazine decanoate suppliers	Direct price and supply competition
Oral fluphenazine	Lower-cost substitute, but weaker adherence profile
Haloperidol decanoate	Direct depot competitor with similar first-generation positioning
Risperidone long-acting injection	Second-generation alternative
Paliperidone palmitate	Higher-priced, more commercially supported alternative
Aripiprazole long-acting injections	Compete through newer safety and tolerability positioning

The product is vulnerable to supplier concentration. A small market can support only limited manufacturers, and one discontinuation or manufacturing interruption can affect availability disproportionately. FDA’s Drug Shortages database and product discontinuation notices are important indicators for this category.[4]

What is the financial trajectory for Prolixin Decanoate?

Prolixin Decanoate has a mature, low-growth financial profile. No major pharmaceutical company publicly reports standalone revenue for the product. Sales are generally embedded within broader generic injectable, hospital, or specialty pharmaceutical reporting.

Financial driver	Expected effect
Generic price erosion	Reduces unit revenue over time
Limited supplier count	Can support temporary price increases
Hospital and institutional demand	Provides recurring baseline volume
Long-acting administration	Supports clinical persistence but not branded pricing
Manufacturing complexity	Raises cost relative to simple oral tablets
Product shortages	Can create short-term revenue spikes and customer switching
Newer long-acting injectables	Limits long-term volume growth
Lack of patent protection	Prevents durable margin expansion

The product’s financial trajectory is therefore best described as stable-to-declining in nominal market value, with intermittent volatility. Unit demand may remain resilient because schizophrenia is a chronic condition and depot therapy addresses medication adherence. Revenue can still decline if generic prices fall, even when prescription volume is stable.

A manufacturer with an established sterile injectable plant may obtain better economics than a new entrant because the product can use existing vial-filling, inspection, packaging, and distribution infrastructure. The absolute market opportunity remains limited, however. A new entrant would likely evaluate the product as a portfolio filler or supply-reliability asset rather than as a major growth product.

What factors drive demand for Prolixin Decanoate?

Demand is concentrated in patient populations that benefit from long-acting treatment but do not require the newer safety or tolerability profile of second-generation injectables.

Clinical demand

Demand is supported by:

• Chronic schizophrenia maintenance treatment
• Medication nonadherence
• Public-sector and community mental-health programs
• Inpatient-to-outpatient transition protocols
• Patients stabilized on older antipsychotic regimens
• Cost-sensitive formularies

Use is constrained by the adverse-effect profile of first-generation antipsychotics. Many clinicians prefer newer long-acting injectables when formulary coverage, tolerability, and patient-specific factors support their use.

Payer and institutional demand

Fluphenazine decanoate is generally positioned as a low-cost alternative. Medicaid programs, public hospitals, correctional-health systems, and community mental-health providers may retain demand because acquisition cost is materially lower than for patented or recently launched long-acting injectables.

The product also benefits from clinical familiarity. Prescribers and institutions with established depot-antipsychotic protocols may continue using it despite broader availability of newer agents.

How does Prolixin Decanoate compare with newer long-acting antipsychotics?

Product	Active ingredient	Generation	Commercial position	Key competitive issue
Prolixin Decanoate	Fluphenazine decanoate	First	Low-cost mature generic	Safety and tolerability
Haldol Decanoate	Haloperidol decanoate	First	Low-cost mature generic	Similar class limitations
Risperdal Consta	Risperidone	Second	Mature long-acting product	Administration and lifecycle pressure
Invega Sustenna	Paliperidone palmitate	Second	Major branded long-acting product	Higher price, broad adoption
Abilify Maintena	Aripiprazole monohydrate	Second	Branded long-acting product	Tolerability and commercial support
Aristada	Aripiprazole lauroxil	Second	Branded long-acting product	Dosing flexibility and cost

Prolixin Decanoate’s main advantage is price. Its main disadvantages are the clinical limitations associated with first-generation dopamine blockade and the absence of a current branded commercial platform.

Are there Paragraph IV challenges or generic launch risks?

Paragraph IV litigation is unlikely to be a central feature of this product’s current market because the principal product and formulation protections are old. Generic launch risk is instead operational.

Key launch and supply risks include:

• FDA review of sterile injectable manufacturing
• Container-closure integrity
• Particulate and sterility control
• Consistent concentration and labeling
• Active ingredient sourcing
• Limited commercial scale
• Contract manufacturing dependence
• Distribution economics
• Shortage-related regulatory scrutiny

A generic applicant could face a commercial challenge even without patent litigation. The market may be too small to support multiple entrants at attractive margins. A successful approval does not guarantee durable supply or meaningful market share.

What patent litigation affects Prolixin Decanoate?

No major current patent litigation is publicly associated with Prolixin Decanoate as a commercial product. Litigation risk is low relative to newer branded drugs because there is no apparent active patent thicket covering the core compound, route, or depot formulation.

Potential disputes would more likely involve:

• Product liability
• Manufacturing quality
• Distribution contracts
• Supply agreements
• Regulatory enforcement
• Trademark rights relating to the historical Prolixin name

These issues are commercially distinct from Paragraph IV patent litigation.

Are there licensing deals for Prolixin Decanoate?

The product has passed through historical brand, generic, and distribution arrangements, but no current licensing transaction is widely recognized as a major value driver. Any licensing activity would likely involve an ANDA transfer, contract manufacturing agreement, or regional distribution arrangement rather than a strategic global deal.

The economics favor supply agreements tied to manufacturing capacity. A licensee would generally value approved injectable infrastructure and reliable sourcing more than patent rights.

What geographic markets support sales?

The United States is the most relevant market for FDA-approved fluphenazine decanoate products and carries the greatest visibility for shortages, ANDA approvals, and generic competition. International markets may sell fluphenazine depot products under different brand names or generic labels, but regulatory status, supplier participation, and reimbursement vary by country.

Geographic revenue is likely concentrated in:

1. The United States, through institutional, Medicaid, and community-care channels.
2. Selected European and emerging markets where older depot antipsychotics remain available.
3. Public-sector health systems with lower-cost procurement priorities.

The product does not have the global commercial infrastructure associated with newer branded injectable antipsychotics.

How strong is the Prolixin Decanoate patent estate?

The patent estate is weak from a current commercial perspective. Its value lies in market familiarity and manufacturing know-how, not exclusivity.

Strength factor	Rating
Core compound protection	Low
Formulation protection	Low
Method-of-use protection	Low
Device protection	Low
Manufacturing know-how	Moderate at supplier level
Regulatory barriers	Moderate for sterile injectables
Pricing power	Low
Supply scarcity leverage	Moderate but variable
Long-term growth potential	Low

Manufacturing capability is the most important practical barrier. A supplier with an approved sterile injectable facility, validated process, and established hospital distribution can compete effectively even without patent protection.

What generic launch scenarios exist?

Base case

Existing suppliers continue serving a stable niche. Prices remain low, demand persists in public-sector and institutional channels, and revenue declines gradually as newer long-acting antipsychotics gain share.

Shortage-driven upside

A competitor exits or experiences a manufacturing interruption. Remaining suppliers gain temporary volume and may obtain improved pricing. This upside is generally short-lived and depends on restoring market supply.

New entrant scenario

A new manufacturer receives FDA approval and enters with a low-price strategy. Market share shifts quickly, but total market revenue declines because competition intensifies. Profitability depends on production scale and hospital contracting.

Decline scenario

Clinicians increasingly replace fluphenazine decanoate with paliperidone, aripiprazole, or other second-generation long-acting injectables. Volume contracts, leaving the product dependent on a smaller group of legacy patients and cost-sensitive institutions.

Key Takeaways

• Prolixin Decanoate is the historical brand associated with fluphenazine decanoate, a mature first-generation long-acting injectable antipsychotic.
• The product has no meaningful remaining branded exclusivity or commercially relevant patent estate.
• FDA-regulated generic supply, sterile manufacturing, and distribution reliability determine market access.
• No standalone revenue data is publicly reported for Prolixin Decanoate.
• The financial profile is low-growth and likely declining in value, with periodic volatility from shortages and supplier exits.
• Demand persists because of schizophrenia maintenance needs, medication-adherence challenges, and low acquisition cost.
• Paliperidone palmitate and long-acting aripiprazole products are the primary modern commercial competitors.
• Biosimilar risk is not applicable because fluphenazine decanoate is a small-molecule drug.
• Paragraph IV litigation is unlikely to be a material current risk.
• The principal investment opportunity is supply reliability in sterile injectables, not patent monetization.

FAQs

Is Prolixin Decanoate still available in the United States?

Fluphenazine decanoate injection remains the relevant FDA-approved generic product category, but commercial availability can vary by manufacturer, wholesaler inventory, and shortage conditions.[4]

Is Prolixin Decanoate more profitable than oral fluphenazine?

The injectable form can command a higher price per treatment unit than oral tablets, but sterile manufacturing and administration costs are higher. Profitability depends on supply scale and contracting rather than product differentiation.

Does Prolixin Decanoate have an active Orange Book patent?

No commercially significant active patent protection is generally associated with this mature product category. Current FDA application and patent records should be reviewed for any specific marketed product.[3]

Can a company obtain orphan-drug exclusivity for fluphenazine decanoate?

Orphan-drug exclusivity would not ordinarily apply to a long-established drug treating schizophrenia, a common psychiatric indication. The product has no known current orphan exclusivity.

What is the main commercial risk for fluphenazine decanoate manufacturers?

The main risk is low-margin sterile injectable supply. A manufacturer must manage limited market size, price competition, quality requirements, and competition from newer long-acting antipsychotics.

References

1. U.S. Food and Drug Administration. (n.d.). Fluphenazine decanoate injection prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

2. American Psychiatric Association. (2020). The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association Publishing.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/development-approval-process-drugs/orange-book

4. U.S. Food and Drug Administration. (2024). Drug shortages: Fluphenazine decanoate injection. https://www.accessdata.fda.gov/scripts/drugshortages/